CORRESPONDENCE
We read with great interest the News and Views article by Terry J. Smith and Raymond S. Douglas (Pharmacotherapy: Does selenium supplementation improve Graves ophthalmo pathy? Nat. Rev. Endocrinol. 7, 505-506; 2011). 1 The article discussed the study by Marcocci et al. 2 which reported that selenium administration significantly improved quality of life, reduced ocular involvement and slowed progression of the disease in patients with mild Graves ophthalmo pathy (GO) but did not explicate the exact pathomechanism. Smith and Douglas 1 speculated that selenium might influence the sympathetic tone of the ocular muscles and, alternatively, it might reduce inflammation of the superior tarsal muscle of the eyelid. However, we would like to focus on a proinflammatory cyto kine, IL15, in the pathogenesis of GO associated with selenium deficiency.
Although not extensively studied yet, IL15, which is involved in the differentia tion of Thelper 17 cells, has been reported to be related to autoimmune thyroid dis eases (AITD) such as Graves disease and Hashimoto thyroiditis. 3 Higher concentra tions of IL15 were detected in sera from patients with Hashimoto thyroiditis com pared with euthyroid individuals. 4 More over, Pappa et al. 5 detected IL15 in 33% of thyroidassociated ophthalmopathy biopsies from extraocular muscle.
Recently and importantly, Stazi and Trinti 6 demonstrated that selenium deficiency and overexpression of IL15 play a cen tral role in the pathogenesis of AITD, by inhibiting apop tosis, leading to the perpetual inflammation and tissue destruction. Thyroid is especially
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Se Jin Park and Jae Il Shin sensitive to selenium defi ciency because seleno proteins are signi ficant in biosynthesis and activity of thyroid hormones and involved in inhibiting apoptosis. 6 In addition, seleno proteins can modify thyrocytes function by acting as anti oxidants and modifying redox status and thyroid hormone metabolism. 7 In GO, not only deficiency of the essential trace mineral selenium but also overexpression of IL15 may increase activation of effector mechanisms of epithelial damage by stimulat ing proliferation of Thelper 1 cells, cytokine production and intraepithelial lymphocyte cyto toxicity by protecting these lymphocytes from apoptosis. 7 There is a strong association between thyroidassociated ophthalmopathy like GO and Graves disease in about 90% of patients and Hashimoto thyroiditis or a sub clinical form of thyroid autoimmunity in the remain ing 10% of patients with thyroidassociated ophthalmopathy, which suggests that these conditions share a common autoimmune pathogenesis. [8] [9] [10] Therefore, it is possible that selenium deficiency is a formidable risk factor directly leading to thyroid damage through IL15 overexpression in patients with AITDlike GO. Blocking IL15 as well as selenium supplemen tation has the potential to provide a new therapeutic tool to prevent tissue damage of GO. However, further studies are necessary to elucidate the exact molecular role and pathway of IL15 in the development of GO in the future.
